Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rangering i aksjer
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aksjekurs
$4.87
Markedsverdi
$4.36B
Endring (1 dag)
-5.47%
Endring (1 år)
-15.62%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Kategori
Healthcare
P/S-forhold for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
P/S-forhold per October 2026 TTM: 6.59
Ifølge Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 6.59. Ved slutten av 2024 hadde selskapet et P/S-forhold på 11.09.
P/S-historikk for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd fra 2006 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.59 | 9.03% |
| 2025 | 6.04 | -45.55% |
| 2024 | 11.09 | -17.86% |
| 2023 | 13.50 | 42.44% |
| 2022 | 9.48 | -21.14% |
| 2021 | 12.02 | -45.65% |
| 2020 | 22.12 | -9.73% |
| 2019 | 24.50 | 0.76% |
| 2018 | 24.32 | -3.03% |
| 2017 | 25.08 | -11.90% |
| 2016 | 28.47 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 46.19 | -21.47% |
| 2011 | 58.81 | -21.40% |
| 2010 | 74.82 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.72 | 62.80% |
US
|
|
| 41.70 | 533.21% |
US
|
|
| 4.19 | -36.36% |
AU
|
|
| 5.80 | -12.00% |
BE
|
|
| 10.44 | 58.57% |
NL
|
